- Medical Action Industries recalls supply kits
Medical Action Industries has recalled more than 8,000 of its medical convenience kits, which include supplies used for routine medical care, as they include a Chloraprep applicator made by Becton Dickinson, recalled because of the risk of contamination with the fungus Aspergillus penicillioides.
- Boston Scientific recalls two types of stents
Boston Scientific Corporation has recalled its VICI SDS and VICI RDS venous stent systems, which are used to treat obstructions in blocked venous veins, after finding the stents have the potential to migrate or move from where they are initially implanted. There have been 17 complaints and reported injuries related to the recall but no reported deaths. - Abbott recalls nearly 62K pacemakers
Abbott has recalled nearly 62,000 pacemakers after finding they have the potential to short circuit. - Medtronic recalls instructions for its heart pump device
Medtronic has recalled the instructions for its HeartWare Ventricular Assist Device System, which helps the heart pump blood to the rest of the body, to provide updated instructions that address various safety issues. - Novo Nordisk recalls samples of 5 types of insulin
Novo Nordisk has recalled 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy, all types of insulin, after discovering they were stored at temperatures lower than required. The recall only affects product samples and not drug products that have been broadly distributed to pharmacies. - Pfizer recalls lidocaine, bupivacaine after label mix-up
Pfizer’s Hospira business has recalled one lot of 0.5 percent bupivacaine and one lot of 1 percent lidocaine after finding their labels were mixed up. - Pfizer recalls injectable sterile water after finding particulate
Pfizer’s Hospira business has recalled one lot of injectable sterile water after finding a vial containing a visible particulate. - Acella Pharmaceuticals recalls thyroid drug
Acella Pharmaceuticals has recalled 38 lots of its thyroid drug after routine testing conducted by the drugmaker found the drug to be subpotent.
